Funding agencies: CNPq, CAPES, FAPEMIG and Asklepios-Med. NPR is a CNPq SWO scholarship recipient. IGB and ELMV are post-doctoral fellows of CAPES and CNPq, respectively. IBM holds a CNPq undergraduate grant. ALT and HJR are awarded a CNPq fellowship. AP is funded by Asklepios-Med.
Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease
Article first published online: 3 DEC 2013
© 2013 International Parkinson and Movement Disorder Society
Volume 29, Issue 4, pages 527–531, April 2014
How to Cite
Rocha, N. P., Teixeira, A. L., Scalzo, P. L., Barbosa, I. G., de Sousa, M. S., Morato, I. B., Vieira, É. L. M., Christo, P. P., Palotás, A. and Reis, H. J. (2014), Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease. Mov. Disord., 29: 527–531. doi: 10.1002/mds.25752
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 3 APR 2014
- Article first published online: 3 DEC 2013
- Manuscript Accepted: 21 OCT 2013
- Manuscript Revised: 9 OCT 2013
- Manuscript Received: 10 JUN 2013
- non-motor symptoms;
- Parkinson's disease;
- tumor necrosis factor
Inflammatory mechanisms have been implicated in a series of neuropsychiatric conditions, including behavioral disturbances, cognitive dysfunction, and affective disorders. Accumulating evidence also strongly suggests their involvement in the pathophysiology of Parkinson's disease (PD). This study aimed to evaluate plasma levels of inflammatory biomarkers, and their association with cognitive performance and other non-motor symptoms of PD. PD patients and control individuals were subjected to various psychometric tests, including the Mini-Mental State Examination (MMSE), Frontal Assessment Battery (FAB), and Beck's Depression Inventory (BDI). Biomarker plasma levels were measured by enzyme-linked immunosorbent assay (ELISA). PD patients exhibited worse performance on MMSE and the programming task of FAB, and presented higher soluble tumor necrosis factor receptor (sTNFR) plasma levels than control individuals. Among PD patients, increased sTNFR1 and sTNFR2 concentrations were associated with poorer cognitive test scores. After multiple linear regression, sTNFR1 and education remained a significant predictor for FAB scores. Our data suggest that PD is associated with a proinflammatory profile, and sTNFRs are putative biomarkers of cognitive performance, with elevated sTNFR1 levels predicting poorer executive functioning in PD patients. © 2013 International Parkinson and Movement Disorder Society